Medtech bleeds corporate venture cash

Perhaps large healthcare companies have other priorities. Perhaps traditional venture firms have so much money that they are not needed. Whatever the reason, corporate VCs are pulling back from medtech.

In the first three quarters of this year only 15% of the total venture cash received by medtech companies came from rounds with corporate VC participation. This proportion has shrunk fast; two years ago the figure sat at 30%.